在研项目-夺宝岛股份有限公司【官网】

夺宝岛


您好!欢迎访问夺宝岛官方网站。
服务热线:0571-86130357     | 在线反馈English
产品管线图
  • 产品
    靶点
    类型
    临床前
    剂量爬坡
    临床la
    剂量扩展
    临床lb
    临床lla
    关键性试验
    临床llb
    临床lll
    NDA/BLA
    上市
    权益
    合作方
  • 凯美纳®
    (埃克替尼)
    EGFR
    小分子药物
    一线非小细胞肺癌
    二线非小细胞肺癌
    非小细胞肺癌术后辅助治疗
  • 凯美纳®(埃克替尼)项目简介

    盐酸埃克替尼(凯美纳®)是夺宝岛历时近十年自主研发、完全拥有自主知识产权的国家1.1类创新药,也是中国第一个自主创新的小分子靶向抗癌新药。它是一种强效、高选择性的小分子口服表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI),单药适用于治疗表皮生长因子受体(EGFR)基因具有敏感突变的局部晚期或转移性非小细胞肺癌(NSCLC)患者的一线治疗。

  • 贝美纳®
    (恩沙替尼)
    ALK
    小分子药物
    二线非小细胞肺癌
    一线非小细胞肺癌(中国)
    一线非小细胞肺癌(美国)
  • 贝美纳®(恩沙替尼)项目简介

    YANSUANENSHATINI(BEIMEINA®)SHIBEIDAYONGYOUWANQUANZIZHUZHISHICHANQUANDEXINXINGQIANGXIAO、GAOXUANZEXINGDEXINYIDAIJIANBIANXINGLINBALIUJIMEI(ALK)YIZHIJI。YANSUANENSHATINIZHENDUIALKBADIAN,YUALKDEJIEHELIWEIKEZUOTINIDE10BEI,NENGGOUYOUXIAOYIZHIALKDEHUOXING,CONGERQIDAOYIZHIZHONGLIUSHENGZHANGDEZUOYONG。YANSUANENSHATINIZAITIWAIYANJIUHETINEIYANJIUZHONGDOUXIANSHICHULIANGHAOLIAOXIAO,BAOKUODUIKEZUOTINIYIJINGNAIYAODEZHONGLIU,QIEDUIc-met、TRK1/2/3、ROS1DENGBADIANJUNYOUYIZHIZUOYONG。YANSUANENSHATINIZHENDUIALKYANGXINGFEIXIAOXIBAOFEIAI(NSCLC)HUANZHEYIXIANYUKEZUOTINITOUDUITOUDEGUOJIDUOZHONGXINⅢQILINCHUANGSHIYANZHENGZAISHUNLITUIJIN。

  • MIL60
    VEGF
    单克隆抗体
    复发/难治性非小细胞肺癌
    转移性结直肠癌
  • MIL60项目简介

    BEIFAZHUDANKANG(MIL60)(ZHONGZUKANGRENXUEGUANNEIPISHENGZHANGYINZIRENYUANHUADANKELONGKANGTIZHUSHEYE)SHIZHENDUIRENXUEGUANNEIPISHENGZHANGYINZI(VEGF)DEBAXIANGKANGTIYAOWU,SHIBEIFAZHUDANKANGZHUSHEYEDESHENGWULEISIYAO,KEYONGYUZHILIAOFEIXIAOXIBAOFEIAI、JIEZHICHANGAIDENGDUOGESHITILIUSHIYINGZHENG。BEIFAZHUDANKANG(MIL60)TONGGUOYIZHIVEGFYUXUEGUANNEIPIXIBAOBIAOMIANSHOUTI(VEGFR)DEJIEHELAIYIZHIZHONGLIUXUEGUANSHENGCHENG,CONGERJIANGZHONGLIUDEJIYANGQIEDUAN,DADAOZUZHIZHONGLIUSHENGZHANGDEMUDE。BEIFAZHUDANKANG(MIL60)LIANHEKABOHEZISHANCHUNYONGYUYIXIANZHILIAOWANQI、ZHUANYIXINGHUOFUFAXINGFEILINZHUANGXIBAOFEIXIAOXIBAOFEIAIDELINCHUANGSHIYANYIJINGJINRU ⅢQI,MUQIANZHENGZAISHUNLITUIJIN。

  • BPI-D0316
    EGFR
    小分子药物
    一线非小细胞肺癌
    二线非小细胞肺癌²
  • BPI-D0316项目简介

    BPI-D0316SHIZHENDUIT790MTUBIANDEDISANDAIBIAOPISHENGZHANGYINZISHOUTILAOANSUANJIMEIYIZHIJI(EGFR-TKI)。BIAOPISHENGZHANGYINZISHOUTI(EGFR)SHIFEIXIAOXIBAOFEIAIZHUYAODEZHIAIQUDONGYINZI,EGFR-TKINENGTEYIXINGDIYIZHIEGFRDEHUOXING,CONGERDADAOYIZHIZHONGLIUXIBAODEMUDE。MUQIANZHENDUIEGFRTUBIANFEIXIAOXIBAOFEIAIDEZHILIAO,YIDIYIDAIEGFR-TKIWEIZHU,DANSHIHUANZHEZAIJIESHOUDIYIDAIEGFR-TKIZHILIAOYIDINGSHIJIANHOUWANGWANGHUICHANSHENGNAIYAOTUBIAN,QIZHONGT790MTUBIANZHAN60%YISHANG。YANJIUBIAOMING,ZHENDUIT790MTUBIANDEDISANDAIEGFR-TKINENGGOUXIANZHUGAISHANHUANZHEDESHENGCUNZHILIANG,TIGAOHUANZHEDEZONGSHENGCUNQI。BPI-D0316ZAIGUONEIIQILINCHUANGSHIYANZHONGBIAOXIANYOUXIU,MUQIANYIJINGQIDONGLINCHUANGIIQIYANJIU。

  • CM082
    (伏罗尼布)
    VEGFR
    小分子药物
    肾癌
    慢性年龄相关性黄斑病变
  • CM082(伏罗尼布)项目简介

    FULUONIBU(CM082)SHIJUYOUQUANXINHUAXUEJIEGOUDEXINYIDAIDUOBADIANJIMEIYIZHIJI,KEYIZHIZHONGLIUXUEGUANSHENGCHENGJISHENGZHANG,YONGYUDUOZHONGAIZHENGDEZHILIAO。FULUONIBUZHENDUIVEGFR、PDGFR、c-Kit、Flt-3、CSF1RDENGDUOBADIANJUYOUKANGXUEGUANSHENGCHENGDEXIANZHULIAOXIAO,BINGQIENENGGOUMANZUBADIANDETESHU PK/PD YAOQIU,DADAOBAOLIUHUOXING,JIANGDIDUXINGDEMUDE。FULUONIBUYUYIWEIMOSILIANHEYONGYUZHILIAOWANQISHENAIHUANZHEDEⅡ/ⅢQILINCHUANGYANJIU——CONCEPTYANJIUZHENGZAISHUNLITUIJIN,XIANSHILIANGHAODELIAOXIAOHEANQUANXING。

  • 巴替利单抗(Balstilimab)
    PD-1
    单克隆抗体
    宫颈癌,单药治疗
    宫颈癌,联合泽弗利单抗(Zalifrelimab)
  • 巴替利单抗(Balstilimab)项目简介

    巴替利单抗(Balstilimab)是靶向于T细胞上的程序性死亡受体1PD-1)的全人源单克隆抗体,属于免疫检查点抑制剂。巴替利单抗能够有效阻断PD-1与其配体(PD-L1PD-L2)的结合,减少对T细胞的抑制,增强T细胞的效应功能,从而激活免疫系统以攻击肿瘤。巴替利单抗单药以及巴替利单抗联合泽弗利单抗(CTLA-4抗体)拟用于晚期宫颈癌及晚期实体瘤的治疗。巴替利单抗药品临床试验申请已经获得受理,目前正在技术审评。


  • 泽弗利单抗(Zalifrelimab)
    CTLA-4
    单克隆抗体
    宮頸癌,聯合巴替利單抗(Balstilimab)
  • 泽弗利单抗(Zalifrelimab)项目简介

    泽弗利单抗(Zalifrelimab)是靶向于细胞毒性T淋巴细胞相关蛋白4CTLA-4)的全人源单克隆抗体,属于免疫检查点抑制剂。泽弗利单抗通过阻断CTLA-4与其配体(CD80CD86)的结合来抑制CTLA-4T细胞的负调控作用,从而增强肿瘤免疫监视和抗肿瘤反应。泽弗利单抗拟用于联合巴替利单抗(PD-1抗体)治疗晚期宫颈癌及晚期实体瘤。泽弗利单抗药品临床试验申请已经获得受理,目前正在技术审评。


  • BPI-16350
    CDK 4/6
    小分子药物
    实体瘤
  • BPI-16350项目简介

    BPI-16350SHIBEIDAZIZHUYANFADEKANGZHONGLIUXINYAO,SHIJUYOUQUANXINJIEGOUDEXIBAOZHOUQIDANBAIYILAIXINGJIMEI CDK4 HECDK6YIZHIJI。BPI-16350ZHENDUIDEBADIANWEICDK4/6,CDK4/6SHIDIAOJIEXIBAOZHOUQIDEGUANJIANYINZI,NENGGOUCHUFAXIBAOZHOUQICONGSHENGZHANGQI(G1QI)XIANGDNAFUZHIQI(SQI)ZHUANBIAN。BPI-16350NENGTEYIXINGDIHECDK4/6JIEHEERYIZHIQIJIMEIHUOXING,YIZHIAIXIBAOZENGZHI、ZHUANYIDENGXIANGGUANDEXINHAOCHUANDAO,JIANGXIBAOZHOUQIZUZHIYUG1QI,CONGERQIDAOYIZHIZHONGLIUXIBAOZENGZHIDEZUOYONG。BPI-16350YONGYURUXIANAISHIYINGZHENGZHILIAODEYAOPINLINCHUANGSHIYANSHENQINGYIJINGHUOPI,MUQIANZHENGZAISHUNLITUIJIN。

  • BPI-27336
    ERK 1/2
    小分子药物
    实体瘤
  • BPI-27336项目简介

    BPI-27336SHIYIGEYOU夺宝岛ZIZHUYANFADEYONGYOUWANQUANZIZHUZHISHICHANQUANDEXINFENZISHITIHUAHEWU,BAXIANGYIZHIRAS-MAPKTONGLUXIAYOUDEERK1/2。ZAILINCHUANGQIANYANJIUDEDUOZHONGJIBINGMOXINGYOUQISHIKRASTUBIANZHONGLIUMOXINGZHONGXIANSHICHUYOUXIUDEYILIUXIAOGUO,BINGJUYOULIANGHAODEANQUANXING、NAISHOUXINGHEYAODAIDONGLIXUETEZHENG。BPI-27336YOUWANGGAISHANRAS-MAPKTONGLUNAIYAO、TISHENGLIAOXIAO,BINGKEWANGWEIKRASTUBIANZHONGLIUZHEIYIGEWUYAOKEZHIDESHIJIEXINGNANTIDAILAITUPO。BPI-27336XIANGMUIQILINCHUANGYANJIUYIWANCHENGSHOULIESHOUSHIZHERUZU,MUQIANZHENGZAISHUNLITUIJIN。

  • BPI-17509
    FGFR 1/2/3
    小分子药物
    实体瘤
  • BPI-17509项目简介

    BPI-17509SHIBEIDAZIZHUYANFADEYONGYOUQUANXINHUAXUEJIEGOUDEQIANGXIAO、GAOXUANZEXINGCHENGXIANWEIXIBAOSHENGZHANGYINZISHOUTI(FGFR1/2/3)XIAOFENZIKOUFUYIZHIJI,NIYONGYUSHITILIUDENGFGFRJIYINBIANYIDEGELEIZHONGLIUZHILIAO。FGFRZAIZHONGLIUZENGZHI、XUEGUANSHENGCHENG、QIANYIHECUNHUOZHONGQIZHEZHIGUANZHONGYAODEZUOYONG。BPI-17509TONGGUOTEYIXINGYIZHIFGFR1/2/3DEHUOXINGZUZHIXIANGGUANXINHAOCHUANDAODETUJING,JINERYINGXIANGSHENGWUTINEIXIBAOZENGZHI、DIAOWANG、QIANYI、XINSHENGXUEGUANSHENGCHENGDENGDUOGESHENGLIGUOCHENG,ZUIZHONGDADAOYIZHIZHONGLIUSHENGZHANGDEMUBIAO。BPI-17509DEYAOPINLINCHUANGSHIYANSHENQINGYIJINGHUOPI,MUQIANZHENGZAISHUNLITUIJIN。

  • BPI-23314
    BET
    小分子药物
    急性髓系白血病
    实体瘤
  • BPI-23314项目简介

    BPI-23314SHIBEIDAZIZHUYANFADEYONGYOUWANQUANZIZHUZHISHICHANQUANDEXINFENZIHUAHEWU,SHIYIZHONGJUYOUQUANXINJIEGOUDEQIANGXIAO、GAOXUANZEXINGXIUJIEGOUYUHEMODUANWAIJIEGOUYU(Bromodomain and extra-terminal domain, BET)KOUFUXIAOFENZIYIZHIJI。BPI-23314NENGTONGGUOTEYIXINGYIZHIBETJIAZUDANBAIDEGONGNENG,DIAOKONGAIZHENGXIANGGUANJIYINDEZHUANLUBIAODA,JINERYINGXIANGXIBAOSHENGZHANG、ZENGZHI、DIAOWANGDENGDUOGESHENGLIGUOCHENG,ZUIZHONGDADAOYIZHIZHONGLIUSHENGZHANGDEMUBIAO。BPI-23314DEYAOPINLINCHUANGSHIYANSHENQINGYIJINGHUOPI,MUQIANZHENGZAISHUNLITUIJIN。

  • MRX2843
    MerTK/FLT3
    小分子药物
    实体瘤
  • MRX2843项目简介

    MRX2843SHIXINXINGQIANGXIAO、KOUFUSHENGWUKELIYONGXIAOFENZIYIZHIJI,SHIYONGYOUQUANXINHUAXUEJIEGOUDEMerLAOANSUANJIMEI(MerTK)HEFMSYANGLAOANSUANJIMEI3(FLT3)SHUANGZHONGYIZHIJI。MerTKHEFLT3ZAIDUOZHONGZHONGLIUZHONGCUNZAIGUOBIAODAHUOZHEYIBIAN,MRX2843TONGGUOYIZHIZHONGLIUXIBAOYIJIZHONGLIUWEIHUANJINGZHONGGUYOUMIANYIXIBAOSHANGDEMerTKHEFLT3,CONGERYINGXIANGQIGUANJIANXINHAOCHUANDAOTONGLULAIYINGXIANGZHONGLIUSHENGZHANGNENGLIHUOTONGGUOMIANYIDIAOJIEDUIZHONGLIUJINXINGZHILIAO。MRX2843YONGYUWANQISHITILIUDEYAOPINLINCHUANGSHIYANSHENQINGYIJINGHUOPI,MUQIANZHENGZAISHUNLITUIJIN。

  • BPI-28592
    TRK
    小分子药物
    实体瘤⁴
  • BPI-28592项目简介

    BPI-28592SHI夺宝岛ZIZHUYANFADEYONGYOUWANQUANZIZHUZHISHICHANQUANDEXINFENZISHITIHUAHEWU。BPI-28592SHUYUXINXINGTRKYIZHIJI,LINCHUANGQIANYANJIUSHUJUXIANSHI,QIZAIDONGWUTINEIWAISHENGWUXUEHUOXINGYIZHI,NENGYOUXIAOYIZHITRKRONGHETUBIANDEZHONGLIUXIBAOZENGZHI,BINGNENGDUILarotrectinibDENGYIDAITRKYIZHIJINAIYAODETUBIANRUTRKA (G595R)、TRKC(G623R)DENGYOUXIAO,YOUWANGTIGONGYIZHONGXINDEFENZIBAXIANGDEZHILIAOFANGFA,WEITRKTUBIANDEZHONGLIUHUANZHETIGONGGENGDUOYICHU。TRKYIZHIJIBPI-28592PIANDEYAOPINLINCHUANGSHIYANSHENQINGYIHUODEPIZHUN,MUQIANZHENGZAISHUNLITUIJIN。

  • BPI-43487
    FGFR4
    小分子药物
    实体瘤⁵
  • BPI-43487项目简介

    BPI-43487SHIYOU夺宝岛ZIZHUYANFADEYONGYOUWANQUANZIZHUZHISHICHANQUANDEXINFENZISHITIHUAHEWU,SHIYIZHONGQIANGXIAO、GAOXUANZEXINGDEFGFR4GONGJIAFEIKENIYIZHIJI,NIYONGYUCHENGXIANWEIXIBAOSHENGZHANGYINZI19(Fibroblast growth factor-19,FGF19)KUOZENGDEGANXIBAOAI(Hepatocellular carcinoma,HCC)、DANGUANXIBAOAIDENGSHITILIUDEZHILIAO。LINCHUANGQIANSHUJUXIANSHI,BPI-43487DUIFGFR4DEJIEHELIQIANG,DUIQITAFGFRDEXUANZEXINGHAO,TONGSHIJUYOULIANGHAODETINEIDAIXIEXINGZHI,SHIXIANLEYAOXIAOHEYAODAIDONGLIXUEDELIANGHAOPINGHENG,ANQUANXINGFENGXIANJIAOXIAO。MUQIAN,BPI-43487JIAONANGDEYAOPINLINCHUANGSHIYANSHENQINGYIHUOPI,ZHENGZAISHUNLITUIJIN。

  • BPI-361175
    EGFR
    小分子药物
    实体瘤
  • BPI-361175项目简介

    BPI-361175 SHIYIGEYOU夺宝岛ZIZHUYANFADEYONGYOUWANQUANZIZHUZHISHICHANQUANDEXINFENZISHITIHUAHEWU,SHIYIZHONGXINXINGQIANGXIAO、XUANZEXINGDEDISIDAIBIAOPISHENGZHANGYINZISHOUTI(EGFR)KOUFUXIAOFENZIYIZHIJI,NIZHILIAOXIEDAI EGFR C797S TUBIANJIQITA EGFR XIANGGUANTUBIANDEWANQIFEIXIAOXIBAOFEIAIDENGSHITILIU。LINCHUANGQIANSHUJUXIANSHI,BPI-361175TINEIWAISHENGWUXUEHUOXINGYIZHI,NENGYOUXIAOYIZHIXIEDAIEGFR C797STUBIANZHONGLIUXIBAODEZENGZHI,BINGZAIDUOGEXIEDAIEGFRXIANGGUANTUBIANDEYIZHILIUMOXINGSHANGZHANXIANLELIANGHAODEKANGZHONGLIUZUOYONG。BPI-361175YAOPINLINCHUANGSHIYANSHENQINGYIJINGHUOPI,MUQIANZHENGZAISHUNLITUIJIN。

  • BPI-21668
    PIK3CA
    小分子药物
    实体瘤
  • BPI-21668项目简介

    BPI-21668SHIYIGEYOU夺宝岛ZIZHUYANFADEYONGYOUWANQUANZIZHUZHISHICHANQUANDEXINFENZISHITIHUAHEWU,SHIYIZHONGXINXINGQIANGXIAO、GAOXUANZEXINGDELINZHIXIANJICHUN3-JIMEIα(Phosphatidylinositol 3-kinase α, PI3Kα)KOUFUXIAOFENZIYIZHIJI,NIYONGYUPIK3CAJIYINTUBIANDEWANQISHITILIUDEZHILIAO。LINCHUANGQIANSHUJUXIANSHI,BPI-21668ZAIDONGWUTINEIWAISHENGWUXUEHUOXINGYIZHI,NENGYOUXIAOYIZHIDUOZHONGSHITILIUZHONGLIUXIBAOZENGZHI,DANYAOHUOLIANHEYONGYAOZAIDUOGESHITILIUMOXINGSHANGZHANXIANLELIANGHAODEKANGZHONGLIUZUOYONG,LIHUAJIYAODAIDONGLIXUEXINGZHIYOUXIU。BPI-21668YAOPINLINCHUANGSHIYANSHENQINGYIJINGHUOPI,MUQIANZHENGZAISHUNLITUIJIN。

  • MCLA-129
    EGFR/c-MET
    双特异性抗体
    实体瘤
  • MCLA-129项目简介

    MCLA-129SHIZHENDUIEGFRHEc-MetSHUANGBADIANDESHUANGTEYIXINGKANGTI。MCLA-129NENGGOUTONGSHIZUDUANEGFRHEc-MetDEXINHAOCHUANDAO,YIZHIZHONGLIUDESHENGZHANGHECUNHUO,BINGQIETONGGUOZENGQIANGKANGTIYILAIDEXIBAOJIEDAOXIBAODUXINGZUOYONGHETUNSHIZUOYONG(ADCCHEADCP),JINYIBUTIGAODUIAIXIBAODESHASHANGQIANNENG。MCLA-129NIYONGYUEGFRHUOMETYICHANGDEWANQISHITILIUHUANZHEDEZHILIAO。MCLA-129YAOPINLINCHUANGSHIYANSHENQINGYIJINGHUOPI,MUQIANZHENGZAISHUNLITUIJIN。

  • BPI-421286
    KRASG12C
    小分子药物
    实体瘤
  • BPI-421286项目简介

    BPI-421286SHIYIGEQUANXINDE、YONGYOUWANQUANZIZHUZHISHICHANQUANDEXINFENZISHITIHUAHEWU,SHIYIZHONGXINXINGQIANGXIAO、GAOXUANZEXINGDEGONGJIABUKENIKRASG12CKOUFUXIAOFENZIYIZHIJI,NIYONGYUXIEDAIKRASG12CTEYIXINGZHIAIJIYINTUBIANDEBUKEQIECHU、JUBUWANQIHUOZHUANYIXINGSHITILIUHUANZHEDEZHILIAO。LINCHUANGQIANSHUJUXIANSHI,BPI-421286TINEIWAISHENGWUXUEHUOXINGYIZHI,NENGYOUXIAOYIZHIXIEDAIKRASG12CTUBIANZHONGLIUXIBAODEZENGZHI,BINGZAIDUOZHONGXIEDAIKRASG12CTUBIANDEYIZHILIUMOXINGSHANGZHANXIANLELIANGHAODEKANGZHONGLIUZUOYONG。MUQIAN,BPI-421286JIAONANGDEYAOPINLINCHUANGSHIYANSHENQINGYIHUOPI,ZHENGZAISHUNLITUIJIN。

  • 中国
  • 美国

var _hmt = _hmt || []; (function() { var hm = document.createElement("script"); hm.src = "https://hm.baidu.com/hm.js?78ebdacae9da971faf025645ab77d367"; var s = document.getElementsByTagName("script")[0]; s.parentNode.insertBefore(hm, s); })();